Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial)
循环免疫细胞上基线 PD-L1 表达作为接受度伐利尤单抗和卡铂-依托泊苷治疗的广泛期小细胞肺癌患者生存期和免疫相关不良事件的预测因子（NCT04712903 试验）
期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/s12967-026-07896-7
Piedra, Aida; Guinart-Cuadra, Albert; Martínez-Recio, Sergio; Mulet, Maria; Zamora, Carlos; Osuna-Gómez, Rubén; Cantó, Elisabet; Ortiz, Maria Angels; Alejandre, José; Barba, Andrés; Sanz-Beltrán, Judit; Serra-López, Jorgina; Isla, Dolores; Arriola, Edurne; Paz-Ares, Luis; Diz-Taín, María Pilar; Moreno, Alberto Luis; Callejo, Ángel; Vidal, Silvia; Majem, Margarita
